Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Reply: To PMID 22831838.

Yang CH, Yang CM, Ho TC, Lin CP, Huang JS, Chen MS, Lee YA.

Am J Ophthalmol. 2013 May;155(5):954-5. doi: 10.1016/j.ajo.2013.01.033. No abstract available.

PMID:
23582995
2.

Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.

Fingerhut DE, Katz MS, Jonna G.

Am J Ophthalmol. 2013 May;155(5):954. doi: 10.1016/j.ajo.2013.01.034. No abstract available.

PMID:
23582996
3.

Polypoidal choroidal vasculopathy--an important diagnosis to make with therapeutic implications.

Kokame GT.

Retina. 2012 Sep;32(8):1446-8. doi: 10.1097/IAE.0b013e3182695bf8. No abstract available.

PMID:
22922845
4.

Reduced-fluence photodynamic therapy combined with intravitreal bevacizumab for polypoidal choroidal vasculopathy.

Sagong M, Lim S, Chang W.

Am J Ophthalmol. 2012 May;153(5):873-882.e2. doi: 10.1016/j.ajo.2011.09.031. Epub 2012 Jan 20.

PMID:
22265146
5.

Outcomes of polypoidal choroidal vasculopathy treated with ranibizumab monotherapy.

Tan CS, Ngo WK, Lim LW, Cheong KX, Lim TH.

Br J Ophthalmol. 2013 Oct;97(10):1357-8. doi: 10.1136/bjophthalmol-2013-304046. Epub 2013 Aug 20. No abstract available.

PMID:
23962657
6.

Author's response: Outcomes of polypoidal choroidal vasculopathy treated with ranibizumab monotherapy.

Hikichi T.

Br J Ophthalmol. 2014 Apr;98(4):569-70. doi: 10.1136/bjophthalmol-2013-304688. Epub 2013 Dec 16. No abstract available.

PMID:
24344226
7.

Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.

Ricci F, Calabrese A, Regine F, Missiroli F, Ciardella AP.

Retina. 2012 Jul;32(7):1280-8. doi: 10.1097/IAE.0b013e318236e835.

PMID:
22218148
8.

Disadvantages of photodynamic therapy for polypoidal choroidal vasculopathy.

Chhablani JK.

Indian J Ophthalmol. 2010 Nov-Dec;58(6):552-3; author reply 553. doi: 10.4103/0301-4738.71691. No abstract available.

9.

1 - year follow-up after intravitreal bevacizumab alone and in combination with photodynamic therapy for AMD and PCV.

Forte R.

Acta Ophthalmol. 2011 Jun;89(4):e373. doi: 10.1111/j.1755-3768.2010.01991.x. Epub 2010 Oct 7. No abstract available.

10.

One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients.

Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K, Ohtsuka H, Ariga H.

Am J Ophthalmol. 2012 Jul;154(1):117-124.e1. doi: 10.1016/j.ajo.2011.12.019. Epub 2012 Apr 1.

PMID:
22465366
11.

Photodynamic therapy versus combination therapy in polypoidal choroidal vasculopathy: changes of aqueous vascular endothelial growth factor.

Lee MY, Lee WK, Baek J, Kwon OW, Lee JH.

Am J Ophthalmol. 2013 Aug;156(2):343-8. doi: 10.1016/j.ajo.2013.04.001. Epub 2013 May 9.

PMID:
23664208
12.

Two-year outcome of photodynamic therapy combined with intravitreal injection of bevacizumab and triamcinolone acetonide for polypoidal choroidal vasculopathy.

Nakata I, Tsujikawa A, Yamashiro K, Otani A, Ooto S, Akagi-Kurashige Y, Ueda-Arakawa N, Iwama D, Yoshimura N.

Graefes Arch Clin Exp Ophthalmol. 2013 Apr;251(4):1073-80. doi: 10.1007/s00417-012-2137-y. Epub 2012 Aug 25.

PMID:
22923282
13.

Intravitreal bevacizumab as an adjunct in a patient with presumed vascularised choroidal tubercular granuloma.

Babu K, Murthy PR, Murthy KR.

Eye (Lond). 2010 Feb;24(2):397-9. doi: 10.1038/eye.2009.83. Epub 2009 Apr 17. No abstract available.

PMID:
19373263
14.

Argon laser with and without anti-vascular endothelial growth factor therapy for extrafoveal polypoidal choroidal vasculopathy.

Gemmy Cheung CM, Yeo I, Li X, Mathur R, Lee SY, Chan CM, Wong D, Wong TY.

Am J Ophthalmol. 2013 Feb;155(2):295-304.e1. doi: 10.1016/j.ajo.2012.08.002. Epub 2012 Oct 27.

PMID:
23111181
15.

Retinal pigment epithelium tear after intravitreal bevacizumab injection for polypoidal choroidal vasculopathy.

Peng CH, Cheng CK, Chiou SH.

Eye (Lond). 2009 Nov;23(11):2126-9. doi: 10.1038/eye.2008.401. Epub 2009 Jan 23. No abstract available.

PMID:
19169234
16.

Relationship between clinical characteristics of polypoidal choroidal vasculopathy and choroidal vascular hyperpermeability.

Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S.

Am J Ophthalmol. 2013 Feb;155(2):305-313.e1. doi: 10.1016/j.ajo.2012.07.018. Epub 2012 Sep 27.

PMID:
23022162
17.

Reply: To PMID 24999724.

Parodi MB, Iacono P.

Retina. 2015 Apr;35(4):e27-8. doi: 10.1097/IAE.0000000000000572. No abstract available.

PMID:
25784361
18.

Combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.

Lee MY, Kim KS, Lee WK.

Am J Ophthalmol. 2012 May;153(5):1004-5; author reply 1005. doi: 10.1016/j.ajo.2012.01.028. No abstract available.

PMID:
22516155
19.
20.

Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment.

Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y, Miyake M, Ooto S, Tamura H, Yoshimura N.

Am J Ophthalmol. 2012 Jul;154(1):125-36. doi: 10.1016/j.ajo.2012.01.010. Epub 2012 Apr 1.

PMID:
22465368

Supplemental Content

Support Center